Dendritic Cells for the Treatment of Metastatic Renal Cell Carcinoma: At a Low Ebb?

European Urology

Volumn 50, Issue 1, 2006, Pages 11-13

  Patard, Jean Jacques ^a  

^a RENNES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; DENDRITIC CELL VACCINE; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE ACTIVATION; CANCER ADJUVANT THERAPY; CANCER CELL DESTRUCTION; CANCER PATIENT; CLINICAL RESEARCH; DENDRITIC CELL; EDITORIAL; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; LYMPHOCYTE MIGRATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY CELL; MOLECULAR RECOGNITION; NATURAL KILLER T CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

CANCER VACCINES; CARCINOMA, RENAL CELL; DENDRITIC CELLS; HUMANS; IMMUNITY, CELLULAR; KIDNEY NEOPLASMS; NEOPLASM METASTASIS;

EID: 33744921863     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2006.04.022     Document Type: Editorial

References (10)

1. Lam J.S., Belldegrun A.S., and Figlin R.A. Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther 4 (2004) 1081-1096
2. Law T.M., Motzer R.J., Mazumdar M., et al. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma. Cancer 76 (1995) 824-832
3. Figlin R.A., Thompson J.A., Bukowski R.M., et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 17 (1999) 2521-2529
4. Gaugler B., Brouwenstijn N., Vantomme V., et al. A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenetics 44 (1996) 323-330
5. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9 (1991) 271-296
6. Berntsen A., Geertsen P.F., and Svane I.M. Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur Urol 50 (2006) 34-43
7. Coppin C, Porzsolt F, Awa A, Kumpf J, Coldman A, Wilt T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005:CD001425.
8. Escudier B., Szczylik C., Eisen T., et al. Randomized phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC). ASCO annual meeting. J Clin Oncol 23 (2005) (abstract no. 4510)
9. Patard J.-J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49 (2006) 633-643
10. Jocham D., Richter A., Hoffmann L., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363 (2004) 594-599